Ella One Pill: Over-the-Counter Abortion?

Ad Feedback

The Food and Drug Administration could soon approve a new contraceptive pill said to be twice as effective as Plan B, the Morning After pill.

Scientists said the new drug, called Ella One, is longer-lasting than Plan B, since the one-pill treatment can prevent pregnancy up to five days after unprotected sex.

Although it has been described as an emergency contraception, pro-life groups argue the drug is a thinly-veiled attempt to get "abortion over the counter."

"There is no doubt that ulipristal acts an abortifacient, because the drug blocks progesterone receptors at three critical areas," an action that "interferes with the hormone action of progesterone to prepare the endometrium for implantation and to support the early pregnancy," the American Association of Pro Life Obstetricians & Gynecologists wrote in a letter to the FDA earlier this month.

The FDA has already released a statement saying the drug has caused no deaths and had no harmful side-effects during tests conducted by the agency.

But Wendy Wright, president of Concerned Women for America, said the testing wasn't extensive enough to make such a determination.

"There have not been adequate trials done to find out what happens when women take it more than once, or girls under 18 who take it," Wright said.

An FDA panel of experts will decide on Thursday whether Ella One should be approved for use in the U.S. The pill has already been approved in Europe.

Log in or create an account to post a comment.  

CBN IS HERE FOR YOU!

Are you seeking answers in life? Are you hurting? Are you facing a difficult situation?

Find peace with God, discover more about God or send us your prayer request.

Call The 700 Club Prayer Center at 1 (800) 823-6053, 24 hours a day.

A caring friend will be there to pray with you in your time of need.

 CBNNews.com

CBNNews.com

CBN News is a national/international, nonprofit news organization that provides programming by cable, satellite, and the Internet, 24-hours a day. Follow us on Facebook, Twitter, and Google+.